EuroPCR 2018 | SENTINEL: Anatomical Predictors of Stroke during TAVR

The rate of cerebrovascular events in TAVR hovers about 4% in most of the current studies, regardless the center, the operator or the prosthetic valve. At present, no scores can adequately predict which patients run the highest risk of stroke during TAVR, and the routine use of cerebral protection devices remains controversial.

The SENTINEL study randomized 347 patients 2:1 to embolic protection devices during TAVR vs. a control group with no protection. All anatomical data ─valve, aorta and extra cranial vessels─ were collected and analyzed.

 

Anatomical variations such as type of arch, root angulation and amount of calcium, can increase the chance of stroke. However, device benefits were consistent across subgroups.


Read also: EuroPCR 2018 | NOTION: Good TAVR Durability Compared with Surgically-Implanted Valve in Low-Risk Patients.


Paradoxically, the greatest events reduction using cerebral protection devices was observed in patients with lower calcium burden. This might be due to the more friable nature of perivalvular tissue at higher risk of embolization.

 

This information confirms the unpredictable nature of periprocedural stroke and supports the routine use of cerebro-embolic protection devices until more, larger, studies come along.

 

Original title: Anatomical predictors of stroke prevention during transcatheter aortic valve implantation – The SENTINEL Trial.

Presenter: Hasan Jilaihawi.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...